<DOC>
	<DOCNO>NCT02934360</DOCNO>
	<brief_summary>The TR ( ACE ) Assay quantitative vitro diagnostic test run TR ( ACE ) Instrument intend measurement high molecular weight human DNA plasma aid monitoring disease progression response therapy recurrent residual disease .</brief_summary>
	<brief_title>TR ( ACE ) Assay Clinical Specimen Study</brief_title>
	<detailed_description>This study establish clinical performance TR ( ACE ) Assay . Deltas serial TR ( ACE ) Assay measurement compare standard care physician clinical assessment RECIST 1.1 criterion evaluation relative previous visit . Significant change serial TR ( ACE ) Assay measurement hypothesize correlate disease progression response .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Nonsmall cell lung : Male Female Adult patient &gt; = 21 year old Breast : Female Adult patient &gt; = 21 year old Previously diagnose one follow cancer : Breast Nonsmall Cell Lung Cancer progress least Stage III high lung cancer , Cancer progress stage IV ( metastatic ) breast cancer Participating standard care cancer therapy require frequent treatment , typically intravenous chemotherapy visit ( determined standard care particular cancer assess ) , minimum three ( 3 ) treatment visit plan 9 month date enrollment clinical assessment conduct Physician assessment obtain two extra whole blood specimen minimum volume 5 mL per treatment visit contraindicate Stage I II Nonsmall Cell Lung Cancer Stage I III breast cancer Pregnant planning become pregnant course study Unable obtain informed consent subject legal representative Life expectancy le 9 month Presence one follow chronic diseases Another type cancer except nonmelanomatous skin tumor Autoimmune disease require DMARDS Biologics Infectious disease require prolong intravenous antibiotic hospitalization Renal disease specifically End Stage Renal Failure Recent ( &lt; 3 week ) major trauma major surgical procedure ( ) radiation therapy prior enrollment study Recent ( &lt; 2 month ) major occlusive arterial event MI CVA prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>cell free DNA</keyword>
	<keyword>biomarker</keyword>
</DOC>